ENGAGE AF-TIMI 48
2013
Effective Anticoagulation with Factor Xa Next Generation in AF
In 21,105 patients with AF at moderate-to-high stroke risk, edoxaban was non-inferior to warfarin for stroke or systemic embolism, with less bleeding.
Result
Primary endpoint: Stroke or systemic embolism
Higher-dose edoxaban non-inferior; major bleed 2.75 %/yr vs 3.43 %/yr; intracranial bleeding roughly halved.
- Subtopic
- Anticoagulation
- Design
- Double-blind, double-dummy RCT
- Relevance
- Important: one of several pillars.
- Cited in
- ESC 2024 AFACC/AHA 2023 AF
- Source
- Giugliano RP, et al. N Engl J Med. 2013;369(22):2093-2104.doi 10.1056/NEJMoa1310907
Discussion & critique
Completed the four-NOAC evidence base. Reduced efficacy at high creatinine clearance led to a US label restriction, a reminder that NOAC dosing is not one-size-fits-all.